{"id":586759,"date":"2022-02-15T19:52:01","date_gmt":"2022-02-15T19:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=586759"},"modified":"2022-02-15T19:52:01","modified_gmt":"2022-02-15T19:52:01","slug":"idiopathic-membranous-nephropathy-market-size-epidemiology-treatment-therapies-and-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-membranous-nephropathy-market-size-epidemiology-treatment-therapies-and-companies-by-delveinsight_586759.html","title":{"rendered":"Idiopathic Membranous Nephropathy Market Size, Epidemiology, Treatment, Therapies, and Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1644900630.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Idiopathic Membranous Nephropathy Market Size, Epidemiology, Treatment, Therapies, and Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1644900630.jpeg\" alt=\"Idiopathic Membranous Nephropathy Market Size, Epidemiology, Treatment, Therapies, and Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Idiopathic Membranous Nephropathy Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s<strong>&nbsp;&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-membranous-nephropathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Idiopathic Membranous Nephropathy Market<\/a> Insights, Epidemiology, and Market Forecast-2032&#8243;&nbsp;<\/strong>report delivers an in-depth understanding of the Idiopathic Membranous Nephropathy, historical and forecasted epidemiology as well as the Idiopathic Membranous Nephropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-membranous-nephropathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Idiopathic Membranous Nephropathy Market<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>North America is expected to hold the dominant position in the global idiopathic membranous nephropathy market due to high prevalence of idiopathic membranous nephropathy in the region.<\/li>\n<li>According to the clinical journal of American Society of Nephrology, 2017, around 12 million people in the age group of 50 to 60 suffer from idiopathic membranous nephropathy every year in North America.<\/li>\n<li>National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network and GlaxoSmithline are currently working together to understand the effect of combination therapy involving belimumab and rituximab on patients suffering from idiopathic membranous nephropathy. The phase II study started in December 2019 and is expected to finish in February 2025.<\/li>\n<li>According to the New England Journal of Medicine, 2019, a clinical trial performed on patients suffering from membranous nephropathy to compare the efficacy of rituximab and cyclosporine, showed that 60% of the patients responded positively to the rituximab treatment. The remaining 40% patients did not show any response to the treatment.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/idiopathic-membranous-nephropathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/idiopathic-membranous-nephropathy-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Membranous nephropathy occurs when the blood vessels in the nephron (filters) of the kidney get damaged. This leads to proteinuria, that is, leakage of proteins in the urine due to thickening of the walls of the blood vessels which increase the chances of kidney failure. There is no specific treatment available for the condition but if treated correctly, it can be controlled. The symptoms include swelling in the legs, weight gain, poor appetite, high cholesterol, fatigue, acute and chronic kidney failure. Two types of membranous nephropathy are primary and secondary membranous nephropathy. Primary membranous nephropathy occurs when the body&lsquo;s antibodies attack healthy cells in the body, and secondary membranous nephropathy occurs due to conditions like hepatitis B, hepatitis C, syphilis, internalization of medications like NSAIDs, gold salts, tumors etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/idiopathic-membranous-nephropathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/idiopathic-membranous-nephropathy-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-membranous-nephropathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Idiopathic Membranous Nephropathy Drugs<\/a>&nbsp;covered<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Olinvo (Oliceridine injection or TRV130)<\/p>\n<p style=\"text-align: justify;\">2. HTX011<\/p>\n<p style=\"text-align: justify;\">3. CR845\/Difelikefalin<\/p>\n<p style=\"text-align: justify;\">4. NTM001<\/p>\n<p style=\"text-align: justify;\">5. PF05089771<\/p>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of&nbsp;Idiopathic Membranous Nephropathy Companies&nbsp;are:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Trevena<\/p>\n<p style=\"text-align: justify;\">2. Heron Therapeutics<\/p>\n<p style=\"text-align: justify;\">3. Cara Therapeutics<\/p>\n<p style=\"text-align: justify;\">4. Neumentum Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">5. Pfizer<\/p>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Idiopathic Membranous Nephropathy<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Idiopathic Membranous Nephropathy<\/p>\n<p style=\"text-align: justify;\">4. Idiopathic Membranous Nephropathy: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Idiopathic Membranous Nephropathy: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Idiopathic Membranous Nephropathy Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Idiopathic Membranous Nephropathy&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Idiopathic Membranous Nephropathy Treatment<\/p>\n<p style=\"text-align: justify;\">11. Idiopathic Membranous Nephropathy&nbsp;Marketed Products<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">12. Idiopathic Membranous Nephropathy&nbsp;Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">13. Idiopathic Membranous Nephropathy: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Idiopathic Membranous Nephropathy<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About Delveinsight:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight Business Research is a leading&nbsp;Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=idiopathic-membranous-nephropathy-market-size-epidemiology-treatment-therapies-and-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-membranous-nephropathy-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/idiopathic-membranous-nephropathy-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-membranous-nephropathy-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=idiopathic-membranous-nephropathy-market-size-epidemiology-treatment-therapies-and-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Idiopathic Membranous Nephropathy Market DelveInsight&#8217;s&nbsp;&#8220;Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2032&#8243;&nbsp;report delivers an in-depth understanding of the Idiopathic Membranous Nephropathy, historical and forecasted epidemiology as well as the Idiopathic Membranous Nephropathy market trends in the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-membranous-nephropathy-market-size-epidemiology-treatment-therapies-and-companies-by-delveinsight_586759.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-586759","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/586759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=586759"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/586759\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=586759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=586759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=586759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}